Add to Twitter
Galderma Announces New England Journal of Medicine Publication from Phase 2 Study of Investigational Therapy Nemolizumab in Patients with Moderate to Severe Prurigo Nodularis
Results from Phase 2 study published in the New England Journal of Medicine.

Nemolizumab met the primary endpoint of a greater improvement in Peak Pruritus Numerical rating scale (PP-NRS) from baseline to Week 4 compared to placebo.

Nemolizumab was recently granted FDA Breakthrough Therapy Designation for the treatment of patients suffering from prurigo nodularis.